In patients with acute severe ulcerative colitis (ASUC), standard infliximab induction therapy has modest efficacy. There are limited data on the short-term or long-term efficacy of accelerated infliximab induction therapy for these patients.
A cute severe ulcerative colitis (ASUC) affects nearly a quarter of patients with ulcerative colitis (UC), often within the first 2 years after diagnosis. [1] [2] [3] [4] [5] One-third of patients are refractory to intravenous corticosteroids, 6 the cornerstone of management of ASUC, and are offered medical rescue therapy or undergo colectomy. [1] [2] [3] [4] [5] A small but important trial by Jarnerot et al 7 established the efficacy of infliximab (IFX) in rescuing steroid-refractory ASUC, reducing the number of patients who needed colectomy during the hospitalization by half. However, one-quarter of patients who received a single intravenous infusion of IFX required colectomy by 3 months. Two prospective clinical trials comparing IFX and cyclosporine demonstrated comparable clinical efficacy of both agents, but nevertheless a significant proportion of patients initiating therapy with standard dose IFX failed to respond and required colectomy. 8, 9 An elegant study by Brandse et al 10 demonstrated that significant fecal losses of IFX occur in the setting of ASUC, suggesting that greater therapeutic benefit may be achieved by attempting to overcome such losses by repeating IFX infusions at a shorter interval than the standard 5 mg/ kg at weeks 0, 2, and 6 induction dosing or at a higher upfront dose. A small but growing body of literature has examined whether an accelerated induction protocol, administering IFX at higher doses or shorter intervals, results in superior outcomes, [11] [12] [13] [14] [15] However, the results of these studies have been mixed and from small patient cohorts. An initial study by Gibson et al 13 demonstrated a benefit with this accelerated induction protocol in the short term; however, other studies failed to demonstrate an advantage to accelerated induction. 12, 14, 15 Limiting interpretation of this data is that each study had small numbers of patients and inadequate statistical power. Survey-based studies have highlighted the considerable variation in IFX dosing in the hospitalized setting, 16 further highlighting the importance of a robust evidence base to guide clinical practice.
We performed this retrospective multicenter study with the following aims: (1) to compare the outcomes of accelerated compared with standard IFX induction in patients with ASUC; and (2) to perform a systematic review and meta-analysis of the literature to determine if accelerated IFX induction is associated with short-or long-term benefits in ASUC.
Methods

Study Population
This retrospective study included patients hospitalized with ASUC at Massachusetts General Hospital (MGH) (Boston, MA), Indiana University Hospital (IUH) (Indianapolis, IN), or Johns Hopkins Hospital (JHH) (Baltimore, MD) who received IFX rescue therapy for steroid-refractory ASUC. Eligible patients received treatment with intravenous corticosteroids (methylprednisolone 60 mg daily or equivalent) and had inadequate clinical and laboratory response after 3-5 days of treatment, and initiated IFX therapy for medical rescue. Patients who had previously received IFX, had Crohn's disease or inflammatory bowel disease unclassified, or with previous inflammatory bowel disease-related surgery were excluded. All patients were tested for Clostridium difficile and cytomegalovirus colitis and were excluded if positive.
Patients were divided into 2 groups based on IFX administration schedule. Those who received IFX at 5 mg/kg at weeks 0, 2, and 6 were considered to have received standard induction. Patients who either had upfront administration of IFX at 10 mg/kg or had received their IFX infusions at shorter intervals were grouped in the accelerated induction group. The choice of regimen varied by provider. At MGH and JHH, patients perceived to have more severe disease clinically or based on endoscopic severity often received upfront 10 mg/kg, while those with partial response to the initial 5 mg/kg dose received either another infusion at the same dose or 10 mg/kg in 3-5 days. At IUH, patients with a C-reactive protein (CRP)/albumin ratio >1 received upfront 10 mg/ kg IFX; responders received a subsequent infusion at 10 mg/kg in 2 weeks while partial or nonresponders received a second dose at 10 mg/kg in 3-5 days.
Covariates and Outcomes
Information on relevant covariates was obtained by review of the medical record by study investigators and included age, sex, duration of disease, age at diagnosis, disease extent per the Montreal classification, prior treatment history for UC, and concomitant immunomodulator use (azathioprine, 6-mercaptopurine, methotrexate). Relevant admission laboratory parameters included hemoglobin, serum albumin, CRP, platelet count, and erythrocyte sedimentation rate. Where flexible sigmoidoscopy was performed, disease was classified as endoscopically severe in the presence of ulcerations and spontaneous bleeding.
Our primary study outcome was colectomy during the index hospitalization. Secondary study outcomes included colectomy at 3, 6, 12, and 24 months after the index hospitalization and length of hospital stay.
What You Need to Know
Background Whether accelerated infliximab dosing (doses higher than 5 mg/kg or at intervals shorter than the standard induction interval) is associated with better outcomes in acute severe ulcerative colitis is not known.
Findings
Although confounding by severity cannot be excluded, accelerated infliximab induction was not associated with reduction in short-or long-term rates of colectomy.
Implications for patient care
There is need for prospective studies to identify patients who are most likely to benefit from an accelerated dosing regimen of infliximab for acute severe ulcerative colitis.
Statistical Analysis
The study was approved by the Institutional Review Board at each of the 3 study sites. Statistical analysis was performed using Stata 13.0 (StataCorp, College Station, TX). Continuous variables were summarized using mean AE SD and compared using the t test while categorical variables were expressed as proportions and compared using the chi-square test. First, we performed univariate logistic regression with in-hospital colectomy as our outcome to identify potential clinical and laboratory predictors including IFX dosing regimen. Multivariable logistic regression was performed including those with a P value <.15 on univariate analysis or those that had been noted to be influential previously. A 2-sided P value <.05 indicated independent statistical significance. Similar analyses were repeated for each of the study outcomes and using linear regression models for our continuous outcome of length of stay.
As selection of IFX dosing was nonrandom, we conducted a propensity score-adjusted analysis 17, 18 assigning each patient a score indicating likelihood of receiving accelerated IFX induction. This included a model incorporating endoscopic severity, number of bowel movements over a 24-hour period, hemoglobin, serum albumin, and CRP levels. This propensity score was then included in the multivariable model. Preplanned subgroup analysis included stratifying by whether patients received an upfront 10-mg/kg infusion as their first dose or whether it was with a step-up protocol of 5-mg/kg infusions administered within a few days of each other (chaser regimen).
Systematic Review and Meta-Analysis
We performed a systematic review of the published literature by searching PubMed/Medline for relevant manuscripts using combination of the MeSH headings infliximab, ulcerative colitis, and hospitalization between 1998 and December 2017. In addition to full-text manuscripts identified, manual review of abstracts from the major gastroenterology conferences (Digestive Diseases Week, Crohn's and Colitis Foundation Annual Conference, United European Gastroenterology Week, and Annual Meeting of the European Crohn's and Colitis Organization) was performed. Two study investigators (D.A., A.N.A.) independently reviewed the identified studies and confirmed eligibility for inclusion in the meta-analysis based on the following criteria: (1) published as an abstract or full text; (2) include patients with steroid-refractory ASUC initiating IFX; (3) present outcomes of both standard and accelerated IFX induction; and (4) provide sufficient information to calculate odds ratio (OR) and 95% confidence interval (CI). From each eligible study, we extracted the number of patients included in the accelerated and standard induction arms, and number of events in each arm. The study outcomes extracted included in-hospital colectomy (or colectomy at 1 month), and surgery at 3, 6, 12, and 24 months after the index hospitalization where available. A DerSimonian and Laird random effects meta-analysis was performed to quantitatively pool the results of the included studies. 19 Metaregression was performed to identify relevant influential predictors. Publication bias was assessed by visual inspection of the funnel plot and Begg and Egger tests.
Results
Study Population
Our study cohort included 213 patients with ASUC receiving IFX rescue therapy (107 MGH, 50 IUH, 56 JHH) between 2005 and 2017. The mean age of the included patients was 31 years, and 40% were women. Table 1 compares the characteristics of patients who received accelerated IFX induction (n ¼ 81) to those who received standard dosing (n ¼ 132). Among the 81 patients in the accelerated IFX group, 21 received 5 mg/kg followed by chaser doses of 5 mg/kg or 10 mg/kg while 60 received an upfront dose of 10 mg/kg as the first dose. Among those in the standard induction, 5-mg/kg chaser arm, and upfront 10-mg/kg arm, there were 97 (73%), 10 (50%), and 53 (88%) patients who received at least 3 In-Hospital and Long-Term Outcomes With Accelerated IFX Induction
The proportion of patients who required in-hospital colectomy was similar between the accelerated (9%) and standard IFX groups (8%) (OR, 1.14; 95% CI, 0.42-3.13; P ¼ .80). We also identified no difference in the length of index hospitalization between the 2 groups (11.3 days vs 12.3 days, P ¼ .48). Examining longer term outcomes at 3, 6, 12, and 24 months also revealed no differences in the rates of colectomy between the 2 groups (Figure 1) . At 2 years after the index hospitalization, 31% of patients in the accelerated IFX group had undergone colectomy compared with 33% of those who received standard IFX induction (OR, 0.95; 95% CI, 0.50-1.82; P ¼ .88). There was no difference in the association between accelerated induction and colectomy outcomes at each of the 3 centers when analyzed separately (Supplementary Table 1) .
On univariate analysis, age at hospitalization (P ¼ .017), serum albumin (P < .001), and pancolitis (P ¼ .06) met our a priori statistical threshold for inclusion in the multivariable model. Endoscopic severity also predicted need for colectomy. Two (5%) patients in the nonsevere colonoscopy group underwent surgery compared with 14 (11%) of those with severe inflammation (Fisher's P ¼ .26). In a multivariable model, additionally adjusting for institution, there was no difference between accelerated and standard IFX in need for colectomy inhospital (OR, 1.35; 95% CI, 0.38-4.83), or at 3, 6, 12, or 24 months ( Table 2 ). The only variable that was consistently an independent predictor of colectomy was low serum albumin. An increase in serum albumin by 1 g/dL was associated with lower likelihood of colectomy (OR, 0.10; 95% CI, 0.03-0.33). This association remained significant until almost 2 years after hospitalization (OR, 0.61; 95% CI, 0.36-1.04; P ¼ .067).
Among those who received accelerated induction, we then compared those who received 10 mg/kg as their first IFX dose to those who received 5 mg/kg and subsequently received either 5 or 10 mg/kg as chaser doses before week 2. On multivariable analysis, compared with those in the latter group, those who had IFX 10 mg/kg upfront had a numerically lower risk of colectomy inhospital (OR, 0.21; 95% CI, 0.04-1.04) and 3 months (OR, 0.33; 95% CI, 0.10-1.05). There remained a lower risk of colectomy at 12 months (P ¼ .03), and 24 months (OR, 0.23; 95% CI, 0.07-0.73; P ¼ .012) in the upfront 10 mg/kg groups. Supplementary Table 2 compares the outcomes of the upfront 10-mg/kg IFX group to standard induction. While there was no statistically significant difference, there were numerically lower rates of inhospital and long-term colectomy in the 10-mg/kg group with a trend toward statistical significance at 2 years (OR, 0.44; 95% CI, 0.18-1.12; P ¼ .08).
Sensitivity and Subgroup Analyses
We performed several sensitivity and subgroup analysis. We repeated the analysis in the subset of patients with available CRP levels and found no statistically significant difference between the 2 IFX induction protocols. Compared with standard IFX induction, accelerated induction was not associated with a significant reduction in risk of colectomy in-hospital (OR, 0.63; 95% CI, 0.13-3.10) or at any other time point when adjusting for admission CRP levels. Subgroup analysis of those with severe endoscopic inflammation (n ¼ 136) also revealed no significant difference between the 2 groups in in-hospital (P ¼ .48) or other outcomes. Restricting the analysis to patients who completed 2 or 3 doses of IFX also did not reveal a reduction or short-or long-term colectomy risk with accelerated IFX induction.
Propensity scores were calculated to determine likelihood of receiving accelerated IFX induction. On adjustment for the propensity score in the multivariable model, there remained no difference between the accelerated and standard induction groups for in-hospital (OR, 0.70; 95% CI, 0.16-3.01), 6-month (P ¼ .75), 12-month (P ¼ .76), or 24-month (P ¼ .62) colectomy. We then stratified patients by whether their CRP-albumin ratio was above or below the median value for the entire cohort (0.29). Accelerated IFX induction as not associated with lower rates of in-hospital colectomy in either of the 2 groups (P for interaction ¼.25).
Systematic Review and Meta-Analysis
The systematic review identified 7 eligible studies (3 full text and 4 abstract) comparing accelerated and standard IFX infusions (Table 3) . [11] [12] [13] [14] [15] 20 This included 181 patients receiving accelerated IFX infusion and 436 on standard IFX infusion. Four studies were from North America, 14, 15, 20 1 was from Europe, 13 and 2 were from Australia. 11, 12 Four studies presented the rates of colectomy in-hospital (3 studies) or at 1 month (1 study) that were pooled together using a random effects model. There was no heterogeneity between the studies (I 2 ¼ 17%). Using a DerSimonian and Laird random effects model, there was no difference in the rate of colectomy with accelerated compared with standard IFX infusions (OR, 0.76; 95% CI, 0.36-1.61; P ¼ .47) (Figure 2) . While there was a trend toward a higher frequency of colectomy at 3 months in the accelerated induction group (OR, 1.93; 95% CI, 0.80-4.66; P ¼ .14), there was no difference at 12 months (OR, 0.96; 95% CI, 0.57-1.60) or 2 years (OR, 1.79; 95% CI, 0.50-6.38) ( Table 4) . Only 2 included studies defined accelerated IFX induction as being an upfront dose of 10 mg/kg. 15, 20 We could not quantitative pool together the 2 studies as 1 provided information only up to 1 year, 15 while the other provided only 2-year data. 20 However, individually, neither study demonstrated 10 mg/kg IFX upfront to be superior to standard induction. Analysis excluding these 2 studies in the meta-analysis revealed no difference between an accelerated 5-mg/kg dose induction regimen or standard IFX induction for in-hospital as well as long-term rates of colectomy.
Discussion
One-third of patients with ASUC fail to respond to intravenous steroid therapy and require either medical rescue therapy or colectomy. 2, 3, 5, 6, 21, 22 Despite IFX being efficacious in this setting, a significant proportion of patients with ASUC do not respond adequately to standard induction dosing. 7, 23 In this multicenter retrospective cohort study, we did not find that an accelerated IFX induction was associated with lower rates of in-hospital, short-term, or long-term colectomy when compared with standard induction dosing. However, among those receiving accelerated induction, upfront administration of 10 mg/kg reduced risk of colectomy in-hospital and at 1 and 2 years when compared with just reducing the interval between 5-mg/kg doses. Our main results were confirmed in a quantitative meta-analysis of published literature.
An elegant study by Brandse et al 10 examined serum and fecal IFX levels in 30 patients with active UC initiating therapy. Nearly two-thirds of the fecal samples demonstrated detectable levels, and patients who were nonresponders at week 2 had greater fecal loses than those who responded. This finding and rate of nonresponse to IFX in ASUC kindled interest in an accelerated induction protocol with either higher doses or more frequent infusions to optimize serum and tissue concentrations and increase rates of response. One of the earliest reports on this was by Gibson et al 13 who reviewed their experience with 50 hospitalized patients, among whom 15 received an accelerated induction regimen, completing 3 doses at 5 mg/kg within 24 days. While the rate of colectomy during induction was lower in the accelerated IFX cohort, there was no difference in colectomy rates at 2 years. Shah et al 15 found no difference in the rate of colectomy by 30 days or 1 year between 26 patients receiving high dose 10 mg/kg and 120 patients receiving standard dose IFX. Similarly, Choy et al 12 also reported no difference in rate of colectomy between accelerated and standard IFX induction while Govani et al 14 noted lower rates of colectomy at 3 months with accelerated IFX induction.
There are several reasons for conflicting results in the literature, and the potential lack of benefit of accelerated IFX regimen in the meta-analysis and our own pooled analysis. First, it may be that there truly is no benefit of an accelerated regimen and need for more than the standard IFX dose represents a marker of severity that predicts need for colectomy irrespective of the therapeutic intervention. Despite greater fecal losses, there was no difference in the serum IFX level between responders and nonresponders in the study by Brandse et al 10 suggesting that beyond a threshold, there may be little incremental benefit. However, the findings could also reflect limitations of the literature. Most individual studies had few patients, limiting statistical power. Second, the studies differed in their definition of accelerated induction, with some using it to exclusively refer to those receiving 10 mg/kg upfront 15 whereas others used the term to comprise any dosing more frequent than the standard induction. 13 Interestingly, we observed in our study that those who received 10 mg/kg upfront as their first dose had lower rates of colectomy than those who got more frequent chaser infusions. Thus, an early, aggressive approach aimed at overcoming fecal losses and achieving optimal serum and tissue IFX levels may be critical to optimizing outcomes in severe colitis. Whether doses even higher than 10 mg/kg may be beneficial in some remains to established. Finally, one can hypothesize that there may be specific subgroups of patients most likely to benefit from an accelerated induction regimen. Some have proposed using CRPalbumin ratio 24 or absolute CRP values to determine who receives more aggressive induction therapy. While we did not note an effect modification by this in our analyses, future prospective studies are important to answer this robustly.
There are many next steps to accurately defining the role of accelerated IFX induction in ASUC. While we did not find a significant benefit of accelerated IFX induction in ASUC, studies were limited by small sample sizes and inability to reliably subgroup patients into smaller strata who may benefit. Larger prospective cohorts are needed to more robustly define if accelerated IFX infusion has an effect. Further effort is also essential to determine if there are prespecified criteria for a priori identifying those who may be most likely to benefit such as has been proposed with using a CRP/albumin ratio. In addition, comparative clinical trials of different strategies are much needed and results of ongoing studies are awaited (NCT02770040, NCT03209232). Third, IFX dose beyond a specific threshold may not yield clinical benefit and there is a need for further translational research into mechanisms for lack of response to IFX. It is plausible that nonresponse to IFX in the setting of ASUC is not pharmacokinetically mediated but rather represents distinct inflammatory pathways in the tissue. 25 Further exploration of such mechanisms can yield novel therapeutic targets.
We readily acknowledge several limitations to our study. First, while it was a multicenter study and among the largest to examine this question thus far, the number of patients was still relatively small, particularly for subgroup analysis and there was heterogeneity in dosing and timing of administration of IFX without a fixed protocol. Owing to the retrospective design, laboratory parameters were not homogenously available at specific time points (such as after the induction) and we did not have information on serum or fecal IFX levels, as this was not systematically available. However, we believe this is useful initial data to inform design of prospective clinical trials going forward.
In conclusion, we did not find accelerated IFX induction to be superior to standard induction in all patients with ASUC. However, confounding by disease severity cannot be excluded, as the common practice at each center was to favor accelerated induction for those felt to have more severe disease. There is a need for prospective randomized clinical trials and larger multicenter prospective cohorts to better identify the optimal medical rescue strategy in patients with ASUC to reduce morbidity and improve patient outcomes. 
